Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT02715011 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG: JNJ-63709178

Sponsor

Janssen Research & Development, LLC